This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT)., Journal of Clinical Oncology, February 2022, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2022.40.4_suppl.280.
You can read the full text:
The following have contributed to this page
